Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Braz. j. med. biol. res ; 40(11): 1447-1454, Nov. 2007. ilus, tab
Article in English | LILACS | ID: lil-464305

ABSTRACT

Ectopic gastric mucosa (EGM) is considered to be a congenital condition. Rare cases of adenocarcinoma have been described. There are no data justifying regular biopsies or follow-up. Cyclooxygenase-2 (COX-2) is a protein involved in gastrointestinal tumor development by inhibiting apoptosis and regulating angiogenesis. The aim of this prospective study was to evaluate COX-2 expression in EGM and compare it with normal tissue and Barrett's esophagus. We evaluated 1327 patients. Biopsies were taken from the inlet patch for histological evaluation and from the gastric antrum to assess Helicobacter pylori infection. Biopsies taken from normal esophageal, gastric antrum and body mucosa and Barrett's esophagus were retrieved from a tissue bank. EGM biopsies were evaluated with respect to type of epithelium, presence of H. pylori, and inflammation. COX-2 was detected by immunohistochemistry using the avidin-biotin complex. EGM islets were found in 14 patients (1.1 percent). Histological examination revealed fundic type epithelium in 58.3 percent of cases, H. pylori was present in 50 percent and chronic inflammation in 66.7 percent. Expression of COX-2 was negative in normal distal esophagus, normal gastric antrum and normal gastric body specimens (10 each). In contrast, EGM presented over-expression of COX-2 in 41.7 percent of cases and Barrett's esophagus in 90 percent of cases (P = 0.04 and 0.03, respectively). COX-2 immunoexpression in EGM was not related to gender, age, epithelium type, presence of inflammation or intestinal metaplasia, H. pylori infection, or any endoscopic finding. Our results demonstrate up-regulation of COX-2 in EGM, suggesting a possible malignant potential of this so-called harmless mucosa.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Choristoma/enzymology , /metabolism , Esophageal Diseases/enzymology , Gastric Mucosa/enzymology , Pyloric Antrum/enzymology , Biopsy , Barrett Esophagus/enzymology , Barrett Esophagus/pathology , Choristoma/pathology , Esophageal Diseases/pathology , Gastric Mucosa/pathology , Helicobacter pylori/isolation & purification , Prospective Studies , Pyloric Antrum/microbiology , Pyloric Antrum/pathology
2.
Braz. j. med. biol. res ; 40(7): 911-918, July 2007. ilus, tab, graf
Article in English | LILACS | ID: lil-455987

ABSTRACT

Ulcerative colitis (UC) is a disease of the colon and rectum characterized by a nonspecific chronic inflammation mediated by the concerted response of cellular and humoral events. Prostaglandins are synthesized by cyclooxygenase (COX)-1 and -2 and exhibit both pro- and anti-inflammatory activity. To evaluate COX-1 and COX-2 immunoexpression in 42 cases of UC and to correlate it with clinicopathological parameters, COX-1 and COX-2 expression was investigated by the immunohistochemistry method. Only patients with all pertinent clinical and evolutive data as well as with adequate biopsy material were included in the study. Fifteen samples of colorectal adenocarcinoma and 14 of large bowel with no histological changes were used for positive and negative controls, respectively. UC patients showed COX-1 immunoreactivity in epithelial cells in 29 percent of the cases and in inflammatory cells in 43 percent. COX-2 positivity in epithelial and inflammatory cells was found in 69 percent of the samples. The comparison between UC and the control groups revealed that the UC group had significantly more positive cases for COX-1 and COX-2 in inflammatory cells. Immunohistochemistry allowed the identification of COX-1 and COX-2 expression in epithelial and inflammatory cells in UC biopsies. No significant difference between COX-1 and COX-2 immunoreactivity in epithelial and inflammatory cells was observed regarding the clinicopathological parameters. COX-2 presented low expression in normal colon and high expression in colorectal adenocarcinoma. COX-2 might play a role in the pathophysiologic processes of inflammatory bowel disease and the development of neoplasia. Treatment with selective COX-2 inhibitors might be an additional option for therapy.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Colitis, Ulcerative/enzymology , Colorectal Neoplasms/enzymology , Cyclooxygenase 1/metabolism , /metabolism , Colitis, Ulcerative/pathology , Colorectal Neoplasms/pathology , Follow-Up Studies , Immunohistochemistry , Severity of Illness Index
3.
Braz. j. med. biol. res ; 38(2): 271-276, fev. 2005. ilus, tab, graf
Article in English | LILACS | ID: lil-393655

ABSTRACT

Laminin levels in ascitic fluid have been proposed as a marker for neoplastic ascites. We compared the concentration of laminin in serum and in ascitic fluid from patients with hepatic cirrhosis and peritoneal carcinomatosis and assessed the diagnostic value of serum laminin levels in differentiating neoplastic from benign ascites. Laminin concentrations were determined by ELISA with antibodies against laminin extracted from the human placenta, in patients with ascites due to peritoneal carcinomatosis (N = 20) and hepatic cirrhosis (N = 33). Patients with infected or hemorrhagic ascites were excluded. The receiver operating characteristic curve was used to determine the sensitivity and specificity of serum laminin for the diagnosis of neoplastic ascites. When compared to the group with cirrhosis, the carcinomatosis group presented significantly higher mean laminin levels in serum (3.3 ± 0.5 vs 2.1 ± 0.4 æg/ml, mean ± SD, P < 0.05) and ascites (2.8 ± 0.5 vs 1.6 ± 0.4 æg/ml, P < 0.05). Although laminin concentration was higher in serum than in ascites, the laminin serum/ascites ratio and serum-ascites gradient did not differ between the studied groups. A significant correlation (r = 0.93, P < 0.0001) was observed between the serum and ascites laminin values. Serum laminin levels >2.25 æg/ml showed 100 percent sensitivity and 73 percent specificity for the diagnosis of neoplastic ascites. Serum concentration seems to be the main determinant of laminin levels in ascitic fluid and its values can be used as a diagnostic parameter in the study of neoplastic ascites.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Ascites/etiology , Ascitic Fluid/chemistry , Laminin/analogs & derivatives , Liver Cirrhosis/complications , Peritoneal Neoplasms/diagnosis , Antigens, Neoplasm , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Laminin/blood , Peritoneal Neoplasms/complications , Sensitivity and Specificity , Biomarkers, Tumor/analysis
4.
Rev. Assoc. Med. Bras. (1992) ; 40(4): 300-2, out.-dez. 1994.
Article in Portuguese | LILACS | ID: lil-147241

ABSTRACT

No Brasil, o hepatocarcinoma näo é frequente. Constituem grupos de risco os portadores de vírus B da hepatite e cirróticos. Os autores descrevem 14 casos de hepatocarcinoma atendidos em 33 meses. OBJETIVO. Analisar as alteraçöes clínicas e laboratoriais dos doentes com hepatocarcinoma atendidos em 33 meses. CASUISTICA. Relatamos 14 casos de hepatocarcinoma atendidos de agosto de 1990 a maio de 1993, sendo dez do sexo masculino, com idade média de 53 anos. RESULTADOS. Os principais sintomas e sinais foram dor, emagrecimento e icterícia. Marcadores virais: 6 HBsAg, 1 HBeAg, 1 anti-HCV. A AFP elevou-se em 92 por cento. Oito tinham cirrose, 11 tumores multicêntricos. O tratamento cirúrgico foi realizado em três doentes, sendo em um ressecçäo parcial de tumor. Quimioterapia sistêmica foi feita em cinco doentes, sem resposta. CONCLUSAO. O carcinoma hepatocelular é uma doença infrequente em nosso meio. A maioria (80 por cento) apresentava doença avançada e 42 por cento dos pacientes foram HBsAg positivos


Subject(s)
Adult , Middle Aged , Humans , Male , Female , Carcinoma, Hepatocellular/diagnosis , Liver Neoplasms/diagnosis , alpha-Fetoproteins/analysis , Hepatitis B Surface Antigens/analysis , Carcinoma, Hepatocellular/etiology , Carcinoma, Hepatocellular/therapy , Liver Cirrhosis/complications , Liver Neoplasms/etiology , Liver Neoplasms/therapy , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL